The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen

Psychopharmacology

Volumn 185, Issue 1, 2006, Pages 104-111

  Wacan, Jennifer J ^a   Reichel, Carmela M ^a   Farley, Cristal M ^a   McDougall, Sanders A ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

AMPT; NPA; Ontogeny; Partial D2 like receptor agonist; Reserpine; Terguride

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE D2 LIKE RECEPTOR AGONIST; DOPAMINE DERIVATIVE; ENZYME INHIBITOR; METIROSINE; PARTIAL AGONIST; PROPYLNORAPOMORPHINE; RESERPINE; TERGURIDE; TYROSINE HYDROXYLASE INHIBITOR; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; LISURIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; FEMALE; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; RAT; SCORING SYSTEM; WEANING; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; EVALUATION; SPRAGUE DAWLEY RAT;

ALPHA-METHYLTYROSINE; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; LISURIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RESERPINE;

EID: 33344462101     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0263-5     Document Type: Article

References (39)

1. Amt J (1983) Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Eur J Pharmacol 91:273-278
2. Amt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60:205-223
3. Arnt J, Hyttel J (1990) Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques. J Neural Transm 80:33-50
4. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Campbell P, Strakowski SM (2004) The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 14:593-600
5. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, Mick E (2005) Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 10:141-148
6. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
7. Burt DR, Creese I, Snyder SH (1977) Antipsychotic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328
8. Carlsson A (1983) Dopamine receptor agonists: intrinsic activity vs. state of the receptor. J Neural Transm 57:309-315
9. Chipkin RE, McQuade RD, Iorio LC (1987) D1 and D2 dopamine binding site up-regulation and apomorphine-induced stereotypy. Pharmacol Biochem Behav 28:477-482
10. Clark D, Hjorth S, Carlsson A (1985a) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62:1-52
11. Clark D, Hjorth S, Carlsson A (1985b) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62:171-207
12. Clark D, Furmidge LJ, Petry N, Tong Z-Y, Ericsson M, Johnson D (1991) Behavioural profile of partial D2 dopamine receptor agonists. I. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology (Berl) 105:381-392
13. Drukarch B, Stoof JC (1990) D-2 dopamine autoreceptor selective drugs: do they really exist? Life Sci 47:361-376
14. Findling RL, Blumer J, Kauffman R, Batterson J, Gilbert D, Bramer S, Marcus R (2003) Aripiprazole in pediatric conduct disorder: a pilot study. Eur Neuropsychopharmacol 13(Suppl 4):S335
15. Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) 81:89-99
16. Hjorth S, Clark D, Carlsson A (1988) Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur J Pharmacol 152:207-215
17. Hoyer D, Boddeke HWGM (1993) Partial agonists, full agonists: dilemmas of definition. Trends Pharmacol Sci 14:270-275
18. Joyce JN (1991) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment. Exp Neurol 113:277-290
19. Kohler WC, Herbster G (1987) Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 37:723-727
20. LaHoste GJ, Marshall JF (1992) Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse 12:14-26
21. LaHoste GJ, Yu J, Marshall JF (1993) Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc Natl Acad Sci USA 90:7451-7455
22. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627
23. Leff SE, Gariano R, Creese I (1984) Dopamine receptor turnover rates are age-dependent. Proc Natl Acad Sci USA 81:3910-3914
24. 2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats. Psychopharmacology (Berl) 178:431-439
25. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M (1987) Relationship between receptor occupancy and response at striatal autoreceptors. Mol Pharmacol 31:592-598
26. Meller E, Enz A, Goldstein M (1988) Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol 155:151-154
27. 2 receptor agonists in infant and weanling rat pups. Psychopharmacology (Berl) 107:39-49
28. Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M (2005) Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 8:489-490
29. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. National Academy Press, Washington, DC
30. Orsini C, Koob GF, Pulvirenti L (2001) Dopamine partial agonist reverses amphetamine withdrawal in rats. Neuropsychopharmacology 25:789-792
31. Pulvirenti L, Koob GF (1994) Dopamine receptor agonists, partial agonists and psycho stimulant addiction. Trends Pharmacol Sci 15:374-379
32. Rubinstein M, Gershanik O, Stefano FJ (1988) Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice. Eur J Pharmacol 148:419-426
33. Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ (1990) Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 252:810-816
34. 2-like agonist on the cocaine-induced behavioral sensitization of preweanling rats. Pharmacol Biochem Behav 76:27-34
35. Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14:455-463
36. Svensson K, Ekman A, Piercey MF, Hoffmann WE, Lum JT, Carlsson A (1991) Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn Schmiedebergs Arch Pharmacol 344:263-274
37. Wachtel H, Dorow R (1983) Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 32:421-432
38. Wachtel H, Rettig K-J, Seltz A (1984) The central dopamine agonistic action of transdihydrolisuride is unmasked at supersensitive receptors. Naunyn Schmiedebergs Arch Pharmacol 325:R80
39. Zorrilla EP (1997) Multiparous species present problems (and possibilities) to developmentalists. Dev Psychobiol 30:141-150